TrialEuropean urology oncology2018

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.

Beth S Woods et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.